Clinical trials: APECED, open to volunteers
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced), Alopecia Areata
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Background: Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy (APECED) is a problem of the immune system. In people with APECED, the immune system makes a mistake and attacks the body.
- Trial name
- NCT05398809
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis
Natural History of Individuals With Immune System Problems That Lead to Fungal Infections
Background: The immune system is made up of special cells, tissues, and organs that fight infections. Problems with this system may lead to frequent, severe, or unusual fungal infections.
- Conditions
- Chronic Mucocutaneous Candidiasis, Invasive Aspergillosis, CARD9, APECED
- Trial name
- NCT01386437
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy Enteritis
Randomized Stepped Wedge Study of Emapalumab in APECED Enteritis
Background: Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), also known as Autoimmune polyendocrine syndrome type-1 (APS-1), is a disease that causes the immune system to attack parts of a person's body.
- Trial name
- NCT07202598
- Testing
- Emapalumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)